Patent Application
20240141361
The present application relates to the technical field of biomedicine, and specifically relates to a gene circuit, an RNA delivery system and a use thereof.
Accompanying this filing is a Sequence Listing entitled “00204-002US1.xml”, created on Jan. 16, 2024 and having 137,635 bytes of data, machine formatted on IBM-PC, MS-Windows operating system. The sequence listing is hereby incorporated herein by reference in its entirety for all purposes.
RNA interference (RNAi) therapy has been considered a promising strategy to treat human diseases since its invention. However, it has faced numerous issues during clinical practice, and the progress of the therapy's development has fallen short of expectations.
It is generally believed that RNA cannot remain stable outside the cell for a long time, because RNA will be degraded into fragments due to the abundance of RNase in the extracellular environment. It is therefore crucial to find a method that can stabilize RNA outside the cell and enable it to enter targeted tissues, thereby enhancing the effect of RNAi therapy.
There are currently several patents concerning siRNA, mainly focusing on the following aspects: 1. Designing siRNA for medical application. 2. Chemically modifying siRNA in order to enhance its stability in vivo and increase the yield. 3. Refining the design of various artificial carriers, including lipid nanoparticles, cationic polymers and viruses, to improve the efficiency of siRNA delivery in vivo. Among them, there are a number of patents regarding the third aspect. The primary cause for this is that researchers have realized the absence of suitable siRNA delivery systems for safely, accurately and efficiently deliver siRNA to target tissues. This challenge has become the fundamental limitation of RNAi therapy.
Chinese patent CN108624590A discloses an siRNA capable of inhibiting the expression of DDR2 gene. Chinese patent CN108624591A discloses an siRNA capable of silencing ARPC4 gene, and the siRNA is modified with α-phosphorus-selenium. Chinese patent CN108546702A discloses an siRNA targeting a long non-coding RNA, DDX11-AS1. Chinese patent CN106177990A discloses an siRNA precursor that can be used for the treatment of various tumors. These patents devise specific siRNAs and target certain diseases caused by genetic mutations.
Chinese patent CN108250267A discloses a polypeptide and a polypeptide-siRNA induced co-assembly, where the polypeptide acts as a carrier of siRNA. Chinese patent CN108117585A discloses a polypeptide to target and to introduce siRNA for promoting apoptosis of breast cancer cells, also utilizing the polypeptide as a carrier of siRNA. Chinese patent CN108096583A discloses a nanoparticle carrier, which can be loaded with siRNA that has curative effect on breast cancer while containing chemotherapeutic drugs. These patents are all inventions on siRNA carriers, whose technical solutions share the common feature of pre-assembling the carrier and siRNA in vitro before introducing them to the host. In fact, this is characteristic for most of the currently designed delivery techniques. However, these delivery systems pose a common issue that such artificially synthesized exogenous delivery system is prone to be cleared by the host's circulatory system, cause immunogenic reactions, and even potentially be toxic to certain cell types and tissues.
The research team of the present invention found that endogenous cells can selectively encapsulate miRNAs into exosomes. Exosomes can deliver miRNA to receptor cells, and the secreted miRNA can effectively block the expression of target genes at a relatively low concentration. Exosomes are biocompatible with the host immune system and possess the inherent ability to protect and transport miRNA across biological barriers in vivo, thereby having the potential to overcome problems associated with siRNA delivery. For example, Chinese patent CN110699382A discloses a method for preparing exosomes delivering siRNA, which involves techniques of isolating exosomes from plasma and encapsulating siRNA into exosomes by electroporation.
However, such techniques for isolating or preparing exosomes in vitro often necessitate obtaining a large amount of exosomes through cell culture, together with the step of siRNA encapsulation, which makes the clinical cost of large-scale application of the product too high for patients to afford. More importantly, the intricate production/purification process of exosomes makes it almost impossible to comply with GMP standards.
So far, medicinal products containing exosomes as active ingredients have not received approval from CFDA. The main challenge lies in ensuring the consistency of exosome products, which results in these products failing to obtain drug production licenses. If this issue can be resolved, it would significantly advance RNAi therapy.
Therefore, the development of a safe, precise and efficient gene circuit and RNA delivery system is a crucial part to improve the efficacy of RNAi therapy and advance it further.
In view of this, the embodiments of the present application provide a gene circuit, an RNA delivery system and a use thereof to solve the technical deficiencies existing in the existing technology.
The present application provides a gene circuit, comprising at least one RNA fragment capable of inhibiting gene expression and/or at least one targeting tag with targeting function, wherein the gene circuit is a sequence capable of enriching and self-assembling in a host organ or tissue to form a complex, and the gene circuit treats a disease by inhibiting the expression of a gene that matches with the RNA fragment.
Optionally, the RNA fragment comprises one, two or more RNA sequences that have medical significance and are capable of being expressed, and the RNA sequence is an siRNA sequence, shRNA sequence or miRNA sequence.
Optionally, the gene circuit further comprises a promoter, and the gene circuit has types of promoter-RNA fragment, promoter-targeting tag, and promoter-targeting tag-RNA fragment.
The gene circuit comprises at least one RNA fragment capable of inhibiting gene expression and at least one targeting tag with targeting function. The RNA fragment and the targeting tag are located in the same gene circuit or in different gene circuits. As such, the gene circuit delivered to the host comprises at least one RNA fragment and one targeting tag. For example, if the gene circuit entering the host comprises promoter-RNA fragment, it must also comprise either promoter-targeting tag or promoter-targeting tag-RNA fragment; if the gene circuit entering the host is promoter-targeting tag-RNA fragment, the promoter-RNA fragment and promoter-targeting tag may or may not be present.
Optionally, the gene circuit further comprises a flanking sequence, a loop sequence and a compensation sequence that facilitate the correct folding and expression of the gene circuit, and the compensation sequence will not be expressed in the target receptor.
The gene circuit has types of 5′ promoter-5′ flanking sequence-RNA fragment-loop sequence-compensation sequence-3′ flanking sequence, 5′-promoter-targeting tag, and 5′ promoter-targeting tag-5′ flanking sequence-RNA fragment-loop sequence-compensation sequence-3′ flanking sequence.
Optionally, the 5′ flanking sequence has a sequence that is identical to or more than 80% homologous with ggatcctggaggcttgctgaaggctgtatgctgaattc (SEQ ID NO:1);
Preferably, the compensation sequence has a reverse complementary sequence to the RNA fragment in which any 1 to 3 bases have been deleted.
More preferably, the compensation sequence has a reverse complementary sequence to the RNA fragment in which any 1 to 3 consecutively arranged bases have been deleted.
Most preferably, the compensation sequence has a reverse complementary sequence to the RNA fragment in which bases at positions 9 and 10 have been deleted.
Optionally, the RNA sequence is 15-25 nucleotides in length. For example, the RNA sequence may be 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length. Preferably, the RNA sequence is 18-22 nucleotides in length.
Optionally, the RNA sequence has a sequence that is identical to, more than 80% homologous with, or of a nucleic acid molecule encoding a sequence selected from the group consisting of siRNA of EGFR gene, siRNA of KRAS gene, siRNA of VEGFR gene, siRNA of mTOR gene, siRNA of TNF-α gene, siRNA of integrin-α gene, siRNA of B7 gene, siRNA of TGF-β1 gene, siRNA of H2-K gene, siRNA of H2-D gene, siRNA of H2-L gene, siRNA of HLA gene, siRNA of GDF15 gene, an antisense strand of miRNA-21, an antisense strand of miRNA-214, siRNA of TNC gene, siRNA of PTP1B gene, siRNA of mHTT gene, siRNA of Lrrk2 gene, siRNA of α-synuclein gene, and a combination thereof. It should be noted that the RNA sequence in “a nucleic acid molecule encoding a sequence selected from” the following herein also includes RNA sequences with more than 80% homology to the above-mentioned RNA sequence.
Wherein, the siRNAs of the above-mentioned genes are RNA sequences that have the function of inhibiting the expression of the gene. Numerous RNA sequences with this function exist and cannot all be listed here, and the following sequences with better effects are provided as examples.
The siRNA of the EGFR gene has a sequence that is identical to or more than 80% homologous with UGUUGCUUCUCUUAAUUC CU (SEQ ID NO:4), AAAUGAUCUUCAAAAGUGCCC (SEQ ID NO:5), UCUUUAAGAAGGAAAGAUCAU (SEQ ID NO:6), AAUAUUCGUAGCAUUUAUGGA (SEQ ID NO:7), UAAAAAUCCUCACAUAUACUU (SEQ ID NO:8), or other sequences that inhibit EGFR gene expression.
The siRNA of the KRAS gene has a sequence that is identical to or more than 80% homologous with UGAUUUAGUAUUAUUUAUGGC (SEQ ID NO:9), AAUUUGUUCUCUAUAAUGGUG (SEQ ID NO:10), UAAUUUGUUCUCUAUAAUGGU (SEQ ID NO:11), UUAUGUUUUCGAAUUUCUCGA (SEQ ID NO:12), UGUAUUUACAUAAUUACACAC (SEQ ID NO:13), or other sequences that inhibit KRAS gene expression.
The siRNA of the VEGFR gene has a sequence that is identical to or more than 80% homologous with AUUUGAAGAGUUGUAUUAGCC (SEQ ID NO:14), UAAUAGACUGGUAACUUUCAU (SEQ ID NO:15), ACAACUAUGUACAUAAUAGAC (SEQ ID NO:16), UUUAAGACAAGCUUUUCUCCA (SEQ ID NO:17), AACAAAAGGUUUUUCAUGGAC (SEQ ID NO:18), or other sequences that inhibit VEGFR gene expression.
The siRNA of the mTOR gene has a sequence that is identical to or more than 80% homologous with AGAUAGUUGGCAAAUCUGCCA (SEQ ID NO:19), ACUAUUUCAUCCAUAUAAGGU (SEQ ID NO:20), AAAAUGUUGUCAAAGAAGGGU (SEQ ID NO:21), AAAAAUGUUGUCAAAGAAGGG (SEQ ID NO:22), UGAUUUCUUCCAUUUCUUCUC (SEQ ID NO:23), or other sequences that inhibit mTOR gene expression.
The siRNA of the TNF-α gene has a sequence that is identical to or more than 80% homologous with AAAACAUAAUCAAAAGAAGGC (SEQ ID NO:24), UAAAAAACAUAAUCAAAAGAA (SEQ ID NO:25), AAUAAUAAAUAAUCACAAGUG (SEQ ID NO:26), UUUUCACGGAAAACAUGUCUG (SEQ ID NO:27), AAACAUAAUCAAAAGAAGGCA (SEQ ID NO:28), or other sequences that inhibit TNF-α gene expression.
The siRNA of the integrin-α gene has a sequence that is identical to or more than 80% homologous with AUAAUCAUCUCCAUUAAUGUC (SEQ ID NO:29), AAACAAUUCCUUUUUUAUCUU (SEQ ID NO:30), AUUAAAACAGGAAACUUUGAG (SEQ ID NO:31), AUAAUGAAGGAUAUACAACAG (SEQ ID NO:32), UUCUUUAUUCAUAAAAGUCUC (SEQ ID NO:33), or other sequences that inhibit integrin-α gene expression.
The siRNA of the B7 gene has a sequence that is identical to or more than 80% homologous with UUUUCUUUGGGUAAUCUUCAG (SEQ ID NO:34), AGAAAAAUUCCACUUUUUCUU (SEQ ID NO:35), AUUUCAAAGUCAGAUAUACUA (SEQ ID NO:36), ACAAAAAUUCCAUUUACUGAG (SEQ ID NO:37), AUUAUUGAGUUAAGUAUUCCU (SEQ ID NO:38), or other sequences that inhibit B7 gene expression.
The siRNA of the TGF-β1 gene has a sequence that is identical to or more than 80% homologous with ACGGAAAUAACCUAGAUGGGC (SEQ ID NO:39), UGAACUUGUCAUAGAUUUCGU (SEQ ID NO:40), UUGAAGAACAUAUAUAUGCUG (SEQ ID NO:41), UCUAACUACAGUAGUGUUCCC (SEQ ID NO:42), UCUCAGACUCUGGGGCCUCAG (SEQ ID NO:43, or other sequences that inhibit TGF-β1 gene expression.
The siRNA of the H2-K gene has a sequence that is identical to or more than 80% homologous with AAAAACAAAUCAAUCAAACAA (SEQ ID NO:44), UCAAAAAAACAAAUCAAUCAA (SEQ ID NO:45), UAUGAGAAGACAUUGUCUGUC (SEQ ID NO:46), AACAAUCAAGGUUACAUUCAA (SEQ ID NO:47), ACAAAACCUCUAAGCAUUCUC (SEQ ID NO:48), or other sequences that inhibit H2-K gene expression.
The siRNA of the H2-D gene has a sequence that is identical to or more than 80% homologous with AAUCUCGGAGAGACAUUUCAG (SEQ ID NO:49), AAUGUUGUGUAAAGAGAACUG (SEQ ID NO:50), AACAUCAGACAAUGUUGUGUA (SEQ ID NO:51), UGUUAACAAUCAAGGUCACUU (SEQ ID NO:52), AACAAAAAAACCUCUAAGCAU (SEQ ID NO:53), or other sequences that inhibit H2-D gene expression.
The siRNA of the H2-L gene has a sequence that is identical to or more than 80% homologous with GAUCCGCUCCCAAUACUCCGG (SEQ ID NO:54), AUCUGCGUGAUCCGCUCCCAA (SEQ ID NO:55), UCGGAGAGACAUUUCAGAGCU (SEQ ID NO:56), UCUCGGAGAGACAUUUCAGAG (SEQ ID NO:57), AAUCUCGGAGAGACAUUUCAG (SEQ ID NO:58), or other sequences that inhibit H2-L gene expression.
The siRNA of the HLA gene has a sequence that is identical to or more than 80% homologous with AUCUGGAUGGUGUGAGAACCG (SEQ ID NO:59), UGUCACUGCUUGCAGCCUGAG (SEQ ID NO:60), UCACAAAGGGAAGGGCAGGAA (SEQ ID NO:61), UUGCAGAAACAAAGUCAGGGU (SEQ ID NO:62), ACACGAACACAGACACAUGCA (SEQ ID NO:63), or other sequences that inhibit HLA gene expression.
The siRNA of the GDF15 gene has a sequence that is identical to or more than 80% homologous with UAUAAAUACAGCUGUUUGGGC (SEQ ID NO:64), AGACUUAUAUAAAUACAGCUG (SEQ ID NO:65), AAUUAAUAAUAAAUAACAGAC (SEQ ID NO:66), AUCUGAGAGCCAUUCACCGUC (SEQ ID NO:67), UGCAACUCCAGCUGGGGCCGU (SEQ ID NO:68), or other sequences that inhibit GDF15 gene expression.
The siRNA of the TNC gene has a sequence that is identical to or more than 80% homologous with AUGAAAUGUAAAAAAAGGGA (SEQ ID NO:69), AAUCAUAUCCUUAAAAUGGAA (SEQ ID NO:70), UAAUCAUAUCCUUAAAAUGGA (SEQ ID NO:71), UGAAAAAUCCUUAGUUUUCAU (SEQ ID NO:72), AGAAGUAAAAAACUAUUGCGA (SEQ ID NO:73), or other sequences that inhibit TNC gene expression.
The siRNA of the PTP1B gene has a sequence that is identical to or more than 80% homologous with UGAUAUAGUCAUUAUCUUCUU (SEQ ID NO:74), UCCAUUUUUAUCAAACUAGCG (SEQ ID NO:75), AUUGUUUAAAUAAAUAUGGAG (SEQ ID NO:76), AAUUUUAAUACAUUAUUGGUU (SEQ ID NO:77), UUUAUUAUUGUACUUUUUGAU (SEQ ID NO:78), or other sequences that inhibit PTP1B gene expression.
The siRNA of the mHTT gene has a sequence that is identical to or more than 80% homologous with UAUGUUUUCACAUAUUGUCAG (SEQ ID NO:79), AUUUAGUAGCCAACUAUAGAA (SEQ ID NO:80), AUGUUUUUCAAUAAAUGUGCC (SEQ ID NO:81), UAUGAAUAGCAUUCUUAUCUG (SEQ ID NO:82), UAUUUGUUCCUCUUAAUACAA (SEQ ID NO:83), or other sequences that inhibit mHTT gene expression.
The siRNA of the Lrrk2 gene has a sequence that is identical to or more than 80% homologous with AUUAACAUGAAAAUAUCACUU (SEQ ID NO:84), UUAACAAUAUCAUAUAAUCUU (SEQ ID NO:85), AUCUUUAAAAUUUGUUAACGC (SEQ ID NO:86), UUGAUUUAAGAAAAUAGUCUC (SEQ ID NO:87), UUUGAUAACAGUAUUUUUCUG (SEQ ID NO:88), or other sequences that inhibit Lrrk2 gene expression.
The siRNA of the α-synuclein gene has a sequence that is identical to or more than 80% homologous with AUAUAUUAACAAAUUUCACAA (SEQ ID NO:89), AAGUAUUAUAUAUAUUAACAA (SEQ ID NO:90), AUAACUUUAUAUUUUUGUCCU (SEQ ID NO:91), UAACUAAAAAAUUAUUUCGAG (SEQ ID NO:92), UCGAAUAUUAUUUAUUGUCAG (SEQ ID NO:93), or other sequences that inhibit α-synuclein gene expression.
It should be noted that the above-mentioned “more than 80% homologous with” a sequence may refer to a homology of 85%, 88%, 90%, 95%, 98%, etc.
Optionally, the targeting tag is a targeting peptide or targeting protein with targeting function.
Optionally, the targeting peptide is selected from the group consisting of RVG targeting peptide, GE11 targeting peptide, PTP targeting peptide, TCP-1 targeting peptide, and MSP targeting peptide;
the targeting protein is selected from the group consisting of RVG-LAMP2B fusion protein, GE11-LAMP2B fusion protein, PTP-LAMP2B fusion protein, TCP-1-LAMP2B fusion protein, and MSP-LAMP2B fusion protein.
Optionally, the RNA fragment includes the RNA sequence and a modified RNA sequence obtained by ribose modification to the RNA sequence. That is to say, the RNA fragment may consist of at least one RNA sequence, at least one modified RNA sequence, or the RNA sequence and the modified RNA sequence.
In the present invention, the isolated nucleic acid also includes variants and derivatives thereof. Those skilled in the art can use common methods to modify the nucleic acid. Such modification includes (but not limited to) methylation modification, hydrocarbon modification, glycosylation modification (such as 2-methoxy-glycosyl modification, hydroxyl-glycosyl modification, saccharide ring modification), nucleic acid modification, peptide fragment modification, lipid modification, halogen modification, and nucleic acid modification (such as “TT” modification). In one embodiment of the present invention, the modification is an internucleotide linkage, for example selected from the group consisting of phosphorothioate, 2′-O methoxyethyl (MOE), 2′-fluoro, alkyl phosphonate, phosphorodithioate, alkyl phosphonothioate, phosphoramidate, carbamate, carbonate, phosphotriester, acetamidate, carboxymethyl ester, and combinations thereof. In one embodiment of the present invention, the modification is a modification of nucleotides, for example, selected from the group consisting of peptide nucleic acid (PNA), locked nucleic acid (LNA), arabinose nucleic acid (FANA), analogs and derivatives thereof, and combinations thereof. Preferably, the modification is 2′ fluoropyrimidine modification. 2′ Fluoropyrimidine modification is to replace the 2′-OH of the pyrimidine nucleotide of RNA with 2′-F. 2′-F modification can make RNA difficult to be recognized by RNase in vivo, thereby increasing the stability of RNA fragment during transportation in vivo.
Optionally, the organ or tissue is liver, and the complex is an exosome.
The present application also provides an RNA delivery system, which comprises the gene circuit and a delivery carrier capable of delivering the gene circuit to a host organ or tissue for enrichment.
Optionally, the delivery carrier containing the gene circuit is capable of being enriched in the host organ or tissue and self-assembled in the host organ or tissue to form a complex, wherein the targeting tag is located on the surface of the complex, and the complex seeks for and binds to a target organ or tissue through the targeting tag, and delivers the RNA fragment into the target organ or tissue.
Optionally, the delivery carrier carries one, two or more of the gene circuit, and comprises at least one RNA fragment and a targeting tag in the gene circuit carried.
Optionally, in the case where the delivery carrier carries two or more of the gene circuits, adjacent gene circuits are linked via a sequence composed of sequences 1-3 (sequence 1-sequence 2-sequence 3);
wherein, sequence 1 is CAGATC, sequence 2 is a sequence of 5-80 bases, and sequence 3 is TGGATC. Preferably, sequence 2 is a sequence of 10-50 bases, more preferably, sequence 2 is a sequence of 20-40 bases.
Optionally, in the case where the delivery carrier carries two or more of the gene circuits, adjacent gene circuits are linked via sequence 4 or a sequence with more than 80% homology to sequence 4;
Optionally, the delivery carrier is a viral carrier or a non-viral carrier;
Preferably, the delivery carrier is an adeno-associated viral vector or a plasmid vector. Wherein, the adeno-associated viral vector is preferably adeno-associated viral vector type 5 (AAV5), adeno-associated viral vector type 8 (AAV8) or adeno-associated viral vector type 9 (AAV9).
Optionally, the delivery system is a delivery system for use in a mammal including human, i.e., the delivery system can be used in a mammal including human.
The present application also provides use of the RNA delivery system as described in any paragraph above in the manufacture of a medicament for treating a disease.
Optionally, the medicament is administered by oral administration, inhalation, subcutaneous injection, intramuscular injection, or intravenous injection. That is, the medicament can be introduced into the body through oral administration, inhalation, subcutaneous injection, intramuscular injection or intravenous injection, and delivered to the target tissue via the RNA delivery system as described in any paragraph above to exert a therapeutic effect.
Optionally, the disease is a cancer, pulmonary fibrosis, colitis, obesity, cardiovascular disease caused by obesity, type 2 diabetes, Huntington's disease, Parkinson's disease, myasthenia gravis, Alzheimer's disease, or graft-versus-host disease.
The dosage form of the medicament may be tablets, capsules, powders, granules, pills, suppositories, ointments, solutions, suspensions, lotions, gels, pastes, etc.
The technical effects of this application include:
The gene circuit provided in this application may comprise only an RNA fragment, or only a targeting tag, or a combination of the RNA fragment and targeting tag. In case that the gene circuit only comprises an RNA fragment, it can inhibit gene expression upon entering the body, thereby inhibiting disease formation and development. In case that the gene circuit only comprises a targeting tag, it has excellent targeting function and can be used in combination with a gene circuit only comprising an RNA fragment, prompting the RNA fragment to quickly reach the target organ or tissue to play a role. In case that the gene circuit is a combination of an RNA fragment and targeting tag, it possesses both targeting and therapeutic functions. Therefore, it can rapidly and precisely reach the target organ or tissue, exert therapeutic effects with high efficiency, and is appropriate for large-scale promotion and application. The gene circuit of this application can be enriched in host organ or tissue such as the liver, and assembled into a complex such as an exosome. Subsequently, the gene circuit can achieve disease treatment under its guidance, leading to good effects while avoiding some toxic and side effects in the existing technology. The gene circuit of this application represents a huge breakthrough in both the biological and medical fields, and as such, is of great milestone significance.
The RNA delivery system provided by this application attaches the gene circuit to the delivery carrier to deliver it into the body, and the gene circuit can be excellently enriched in the host organ or tissue and self-assembled to form a complex. The RNA fragment that exerts the effect is then encapsulated and transported by the complex, with no immune responses, making it healthy and safe. This delivery system can deliver various kinds of small molecule RNA with high versatility. In addition, the preparation of the delivery carrier attached with the gene circuit is cheaper and simpler than the preparation of exosomes or proteins, polypeptides and other substances, and it also allows for the determination of a unified quality standard, enhances stability during using, and yields high economic benefits.
Moreover, the RNA delivery system provided by this application can tightly bind to AGO2 and be enriched into a complex (exosomes) after self-assembly in vivo, which not only prevents its premature degradation and maintains its stability in circulation, but also facilitates receptor cell absorption, intracytoplasmic release and lysosomal escape, and only a low dose is required.
The use of the RNA delivery system provided in this application in the medicament offers a platform of drug delivery that facilitates the establishment of further foundations for RNA drug research and development. This significantly advances the development and utilization of RNA drugs.
Specific embodiments of the present application will be described below in conjunction with the accompanying drawings.
First, the technical terms, experimental methods, etc. involved in the present invention are explained.
Hematoxylin-eosin staining, referred to as HE staining, is one of the most basic and widely used technical methods in the teaching and scientific research of histology and pathology.
Hematoxylin stain is alkaline and can stain the basophilic structures of tissues (such as ribosomes, nuclei and ribonucleic acid in the cytoplasm, etc.) into blue-purple, and eosin is an acidic dye that can stain eosinophilic structures of tissues (such as intracellular and intercellular proteins, Lewy bodies, Mallory bodies, and most of the cytoplasm) into pink, making the morphology of the entire cell tissue clearly visible.
The specific steps of HE staining include: sample tissue fixation and sectioning; tissue sample deparaffinizing; tissue sample hydration; hematoxylin staining of tissue sections, differentiation and anti-blue; eosin staining of tissue sections and dehydration; air-drying and sealing tissue sample sections; and finally, observation and taking pictures under a microscope.
Masson's staining makes collagen fibers blue (stained by aniline blue) or green (stained by bright green), and muscle fibers red (stained by acid fuchsin and ponceau), and is related to the size of the anionic dye molecules and the permeability of the tissue. The fixated tissue is stained sequentially or mixed with a series of anionic water-soluble dyes. It can be found that red blood cells are stained by the smallest molecular anionic dyes, muscle fibers and cytoplasm are stained by medium-sized anionic dyes, and collagen fibers are stained by macromolecular anionic dyes. This shows that red blood cells are the least permeable to anionic dyes, followed by muscle fibers and cytoplasm, while collagen fibers have the greatest permeability. Type I and type III collagen are green (GBM, TBM, mesangial matrix and renal interstitium are green), and eosinophilic proteins, renal tubular cytoplasm and red blood cells are red.
The specific steps of Masson's staining include:
Fixing the tissue in Bouin's solution, rinsing with running water overnight, and routinely dehydrating and embedding; deparaffinizing and dehydrating sections (deparaffinizing in xylene for 10 minx 3 times, absorbing the liquid with absorbent paper; 100% ethanol for 5 min×2 times, absorbing the liquid with absorbent paper; 95% ethanol for 5 min×2 times, absorbing the liquid with absorbent paper; rinsing with running water for 2 min, absorbing the liquid with absorbent paper); staining with Weigert's iron hematoxylin for 5-10 min; washing slightly with running water; differentiating with 0.5% hydrochloric acid and alcohol for 15 seconds; rinsing with running water for 3 min; staining with ponceau-fuchsin solution for 8 min; rinsing slightly with distilled water; treating with 1% phosphomolybdic acid aqueous solution for about 5 min; directly counterstaining with aniline blue solution or bright green solution for 5 min without washing with water; treating with 1% glacial acetic acid for 1 min; dehydrating in 95% ethanol for 5 min×2 times, absorbing the liquid with absorbent paper; 100% ethanol for 5 min×2 times, absorbing the liquid with absorbent paper; clearing in xylene for 5 min×2 times, absorbing the liquid with absorbent paper; and sealing with neutral gum.
Western Blot transfers proteins to a membrane and then uses antibodies for detection. For known expressed proteins, the corresponding antibodies can be used as primary antibodies for detection. For the expression products of new genes, the antibodies against the fusion part can be used for detection.
In Western Blot, polyacrylamide gel electrophoresis is employed, where the detected object is protein, the “probe” is an antibody, and the “color development” uses a labeled secondary antibody. The protein sample separated by PAGE is transferred to a solid-phase carrier (such as nitrocellulose film), where it is absorbed through non-covalent bonds without changing the type or biological activity of the polypeptide separated by electrophoresis. The protein or peptide on the solid-phase carrier acts as an antigen and reacts immunologically with the corresponding antibody. Then, it reacts with the second antibody labeled with either enzyme or isotope. The protein component expressed by the specific target gene is separated through electrophoresis and detected through substrate color development or autoradiography. The process primarily comprises of extracting proteins, quantifying proteins, preparing gels, running electrophoresis, transferring membranes, performing immunolabeling, and developing.
Immunohistochemistry (also known as immunocytochemistry), based on the antigen-antibody reaction, i.e., the principle of specific binding of antigen and antibody, is the process of identifying antigens (polypeptides or proteins) in tissue cells, determining their localization, and studying them qualitatively and relative quantitatively by chemical reaction of the chromogenic agent (fluorescein, enzyme, metal ion, or isotope) of the labeled antibody to develop color.
The main steps of immunohistochemistry include soaking sections, airing overnight, deparaffinizing in xylene followed by alcohol of gradient concentrations (100%, 95%, 90%, 80%, 75%, 70%, 50%, 3 min each time), using double distilled water, adding dropwise 3% hydrogen peroxide solution to remove catalase, washing with water, repairing antigen, adding dropwise 5% BSA, blocking for 1 h, diluting primary antibody, washing with PBS buffer, incubating with secondary antibody, washing with PBS buffer, developing color with chromogenic solution, washing with water, staining with hematoxylin, dehydrating with ethanol of gradient concentrations, and sealing with neutral gum.
The detection of siRNA, protein and mRNA levels involved in the present invention is all performed by injecting an RNA delivery system into mice to establish an in vitro mouse stem cell model. qRT-PCR is used to detect the expression levels of mRNA and siRNA in cells and tissues. The absolute quantification of siRNA is determined by drawing a standard curve with a standard product. The expression level of each siRNA or mRNA relative to the internal reference can be represented by 2-ΔCT, where ΔCT=Csample-Cinternal reference. The internal reference gene used is U6 snRNA (in tissue) or miR-16 (in serum, exosomes) molecules when amplifying siRNA, and is GAPDH or 18s RNA when amplifying mRNA. Western blotting is used to detect the expression level of proteins in cells and tissues, and ImageJ software is used for protein quantitative analysis.
In the present invention, unless otherwise specified, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Moreover, the reagents, materials and procedures used herein are all reagents, materials and procedures widely used in the corresponding fields.
In this example, a gene circuit is provided, which comprises at least one RNA fragment capable of inhibiting gene expression and/or at least one targeting tag with targeting function. The gene circuit can be delivered into a host, enriched and self-assembled in the host organ or tissue to form a complex, and achieves the treatment of a disease by inhibiting the expression of a gene with the RNA fragment.
Wherein, the above-mentioned gene refers to the gene that is directly or indirectly related to the occurrence or development of a disease, and the RNA fragment can inhibit the occurrence and development of the disease by inhibiting the expression of the gene, so as to achieve the purpose of treating the disease. The targeting tag can accurately guide the RNA fragment to the lesion area and provide efficient treatment to the lesion area. The host organ or tissue is the liver, and the complex is an exosome.
Specifically, at least one gene circuit is delivered into the host, and the gene circuit delivered into the host comprises at least one RNA fragment and one targeting tag, wherein the RNA fragment and the targeting tag are located in the same gene circuit or in different gene circuits.
In practical applications, the gene circuit also comprises a promoter, preferably a CMV promoter.
The types of the gene circuits include promoter-RNA fragment, promoter-targeting tag, and promoter-targeting tag-RNA fragment.
More specifically, the gene circuit also comprises a flanking sequence, compensation sequence and loop sequence. The flanking sequence, loop sequence and compensation sequence are sequences that enable the sequence to fold into the correct structure and be expressed.
The types of the gene circuit include 5′-promoter-5′ flanking sequence-RNA fragment-loop sequence-compensation sequence-3′ flanking sequence, 5′-promoter-targeting tag, and 5′-promoter-targeting tag-5′ flanking sequence-RNA fragment-loop sequence-compensation sequence-3′ flanking sequence.
In
Wherein, the 5′ flanking sequence preferably has a sequence that is identical to or more than 80% homologous with ggatcctggaggcttgctgaaggctgtatgctgaattc (SEQ ID NO:1), including sequences with 85%, 90%, 92%, 95%, 98%, or 99% homology with
The loop sequence preferably has a sequence that is identical to or more than 80% homologous with gttttggccactgactgac (SEQ ID NO:2), including sequences with 85%, 90%, 92%, 95%, 98%, 99% homology with gttttggccactgactgac (SEQ ID NO:2).
The 3′ flanking sequence preferably has a sequence that is identical to or more than 80% homologous with accggtcaggacacaaggcctgttactagcactcacatggaacaaatggcccagatctggccgcactcgag (SEQ ID NO:3), including sequences with 85%, 90%, 92%, 95%, 98%, 99% homology with
The compensation sequence is the reverse complementary sequence of the RNA fragment with any 1-5 bases deleted. In the case where the RNA fragment contains only one RNA sequence, the compensation sequence may be the reverse complementary sequence of the RNA sequence with any 1-5 bases deleted.
Preferably, the compensation sequence is the reverse complementary sequence of the RNA fragment with any 1-3 bases deleted. In the case where the RNA fragment contains only one RNA sequence, the compensation sequence may be the reverse complementary sequence of the RNA sequence with any 1-3 bases deleted.
More preferably, the compensation sequence is the reverse complementary sequence of the RNA fragment with any 1-3 contiguous bases deleted. In the case where the RNA fragment contains only one RNA sequence, the compensation sequence may be the reverse complementary sequence of the RNA sequence with any 1-3 contiguous bases deleted.
Most preferably, the compensation sequence is the reverse complementary sequence of the RNA fragment with the base at position 9 and/or 10 deleted. In the case where the RNA fragment contains only one RNA sequence, the compensation sequence may be a reverse complementary sequence of the RNA sequence with the base at position 9 and/or 10 deleted. Deleting the base at position 9 and/or 10 has the best effect.
It should be noted that the above-mentioned flanking sequence, compensation sequence, and loop sequence are not randomly selected, but are determined based on a large number of theoretical studies and experiments. With the cooperation of the above-mentioned certain flanking sequence, compensation sequence, and loop sequence, the expression rate of RNA fragments can be maximized.
The above sequences are specifically shown in Table 1 below.
The RNA fragment may comprise one, two or more RNA sequences that have medical significance and are capable of being expressed, and the RNA sequence may be an siRNA sequence, shRNA sequence or miRNA sequence, preferably an siRNA sequence.
The length of an RNA sequence is 15-25 nucleotides (nt), preferably 18-22 nt, such as 18 nt, 19 nt, 20 nt, 21 nt, or 22 nt. The range of the sequence length is not chosen arbitrarily but was determined after repeated trials. A large number of experiments have proved that in the case where the length of the RNA sequence is less than 18 nt, especially less than 15 nt, the RNA sequence is mostly invalid and will not play a role. In the case where the length of the RNA sequence is greater than 22 nt, especially greater than 25 nt, not only does the cost of the gene circuit increase greatly, but the effect is no better than that of an RNA sequence with a length of 18-22 nt, and the economic benefits are poor. Therefore, in the case where the length of the RNA sequence is 15-25 nt, especially 18-22 nt, the cost and function can be balanced with the best effect.
RNA sequences of different lengths are shown in Table 2 below.
Preferably, the above-mentioned RNA sequence has a sequence that is identical to, more than 80% homologous with, or of a nucleic acid molecule encoding a sequence selected from the group consisting of siRNA of EGFR gene, siRNA of KRAS gene, siRNA of VEGFR gene, siRNA of mTOR gene, siRNA of TNF-α gene, siRNA of integrin-α gene, siRNA of B7 gene, siRNA of TGF-β1 gene, siRNA of H2-K gene, siRNA of H2-D gene, siRNA of H2-L gene, siRNA of HLA gene, siRNA of GDF15 gene, an antisense strand of miRNA-21, an antisense strand of miRNA-214, siRNA of TNC gene, siRNA of PTP1B gene, siRNA of mHTT gene, siRNA of Lrrk2 gene, siRNA of α-synuclein gene, and a combination thereof.
The siRNAs and the antisense strands of miRNAs of the above-mentioned genes can inhibit the expression or mutation of the genes and miRNAs, thereby achieving the effect of inhibiting diseases. These diseases include, but are not limited to: cancer, pulmonary fibrosis, colitis, obesity, cardiovascular disease caused by obesity, type 2 diabetes, Huntington's disease, Parkinson's disease, myasthenia gravis, Alzheimer's disease, graft-versus-host disease and related diseases. The related diseases herein refer to the associated diseases, complications or sequelae that appear during the formation or development of any one or several of the above diseases, or other diseases that are related to the above diseases to a certain extent. Among them, cancers include but are not limited to: gastric cancer, kidney cancer, lung cancer, liver cancer, brain cancer, blood cancer, bowel cancer, skin cancer, lymphatic cancer, breast cancer, bladder cancer, esophageal cancer, head and neck squamous cell carcinoma, hemangioma, glioblastoma, or melanoma.
Preferably, the above-mentioned RNA fragment can also be obtained by ribose modification of the RNA sequence (siRNA, shRNA or miRNA), preferably 2′ fluoropyrimidine modification. 2′ Fluoropyrimidine modification is to replace the 2′-OH of the pyrimidine nucleotide of siRNA, shRNA or miRNA with 2′-F. 2′-F modification can make siRNA, shRNA or miRNA difficult to be recognized by RNase in the human body, thereby increasing the stability of RNA fragment during transportation in vivo.
The targeting tag can be selected from one of targeting peptides, targeting proteins or antibodies with targeting functions. Wherein, targeting peptides include but are not limited to RVG targeting peptide (with the nucleotide sequence as shown in SEQ ID No: 1), GE11 targeting peptide (with the nucleotide sequence as shown in SEQ ID No: 2), PTP targeting peptide (with the nucleotide sequence as shown in SEQ ID No: 3), TCP-1 targeting peptide (with the nucleotide sequence as shown in SEQ ID No: 4), or MSP targeting peptide (with the nucleotide sequence as shown in SEQ ID No: 5); targeting proteins include but are not limited to RVG-LAMP2B fusion protein (with the nucleotide sequence as shown in SEQ ID No: 6), GE11-LAMP2B fusion protein (with the nucleotide sequence as shown in SEQ ID No: 7), PTP-LAMP2B fusion protein (with the nucleotide sequence as shown in SEQ ID No: 8), TCP-1-LAMP2B fusion protein (with the nucleotide sequence as shown in SEQ ID No: 9), or MSP-LAMP2B fusion protein (with the nucleotide sequence as shown in SEQ ID No: 10).
Among them, RVG targeting peptide and RVG-LAMP2B fusion protein can precisely target brain tissue; GE11 targeting peptide and GE11-LAMP2B fusion protein can precisely target organs or tissues with high expression of EGFR, such as lung cancer tissue with EGFR mutation; PTP targeting peptide and PTP-LAMP2B fusion protein can precisely target the pancreas, especially the plectin-1 protein specifically expressed in human and mouse pancreatic cancer tissues; TCP-1 targeting peptide and TCP-1-LAMP2B fusion protein can precisely target the colon; and MSP targeting peptide and MSP-LAMP2B fusion protein can precisely target muscle tissue.
In practical applications, the targeting tag can be flexibly matched with various RNA fragments, and different targeting tags can play different roles with different RNA fragments. For example, RVG targeting peptide and RVG-LAMP2B fusion protein can be combined with siRNA of EGFR gene, siRNA of TNC gene or a combination of the two to treat glioblastoma, be combined with siRNA of PTP1B gene to treat obesity, be combined with siRNA of mHTT gene to treat Huntington's disease, or be combined with siRNA of LRRK2 gene to treat Parkinson's disease; GE11 targeting peptide and GE11-LAMP2B fusion protein can be combined with siRNA of EGFR gene to treat lung cancer and other diseases induced by high expression or mutation of EGFR gene; TCP-1 targeting peptide or TCP-1-LAMP2B fusion protein can be combined with siRNA of TNF-α gene, siRNA of integrin-α gene, siRNA of B7 gene or any combination of the above three to treat colitis or colon cancer.
It should be noted that the gene circuit provided in this example may comprise only an RNA fragment, or only a targeting tag, or a combination of the RNA fragment and targeting tag. In case that the gene circuit only comprises an RNA fragment, it can inhibit gene expression upon entering the body, thereby inhibiting disease formation and development. In case that the gene circuit only comprises a targeting tag, it has excellent targeting function and can be used in combination with a gene circuit only comprising an RNA fragment, prompting the RNA fragment to quickly reach the target organ or tissue to play a role. In case that the gene circuit is a combination of an RNA fragment and targeting tag, it possesses both targeting and therapeutic functions. Therefore, it can rapidly and precisely reach the target organ or tissue, exert therapeutic effects with high efficiency, and is appropriate for large-scale promotion and application.
On the basis of Example 1, an RNA delivery system is provided in this example, which comprises the gene circuit as described in Example 1 and a delivery carrier capable of delivering the gene circuit to the host organ or tissue for enrichment.
The delivery carrier carrying the gene circuit can be enriched in the host organ or tissue and endogenously spontaneously form a complex in the host organ or tissue. The targeting tag is located on the surface of the complex, and the complex seeks for and binds to the target organ or tissue through the targeting tag, and delivers the RNA fragment into the target organ or tissue. The above-mentioned organ or tissue is the liver, the complex is an exosome, and the target tissue is the organ or tissue that needs treatment.
Specifically, the liver will phagocytize the exogenous delivery carrier, and up to 99% of the exogenous delivery carrier will enter the liver, so the delivery carrier does not need to be specifically designed to be enriched in liver tissue. The exogenous delivery carrier is then opened to release the RNA fragment (siRNA, shRNA, or miRNA). The liver tissue spontaneously encapsulates the RNA fragment into exosomes, and these exosomes become RNA delivery mechanisms.
The siRNA precursor sequence is shown in Table 3 below.
Preferably, in order to enable the RNA delivery mechanism (exosome) to have the ability of “precise guidance”, a targeting tag in the gene circuit of the delivery carrier is designed, and the targeting tag will also be self-assembled into the exosome by the liver tissue, especially when selecting certain targeting tags, they can be inserted into the surface of exosomes to become a targeting structure that can guide exosomes. For example, when the targeting tag is a targeting protein, the targeting tag is anchored on the surface of exosomes through membrane proteins (preferably Lamp2b), thereby guiding the delivery of exosomes to the target tissue, which greatly improves the accuracy of the RNA delivery system described in the present invention. On the one hand, it can greatly reduce the amount of exogenous delivery carriers that need to be introduced, and on the other hand, it greatly improves the efficiency of potential drug delivery.
In practical applications, the delivery carrier can carry one, two or more gene circuits as described in Example 1. For example, if brain glioma needs to be treated, a gene circuit comprising siRNA of EGFR gene and a gene circuit comprising siRNA of TNC gene can both be used on the same delivery carrier (with or without a targeting tag, a better effect with a targeting tag); if enteritis needs to be treated, a gene circuit comprising siRNA of TNF-α gene, a gene circuit comprising siRNA of integrin-α gene, and a gene circuit comprising siRNA of B7 gene can all be used on the same delivery carrier (with or without a targeting tag, a better effect with a targeting tag); if Huntington's disease needs to be treated, a gene circuit comprising only siRNA of mHTT gene can be used on a delivery carrier, or a gene circuit comprising both siRNA of mHTT gene and a target tag can be used, or a gene circuit comprising siRNA of mHTT gene and a gene circuit comprising a target tag can both be used.
In the case where the delivery carrier carries two or more gene circuits, adjacent gene circuits can be linked via sequence 1-sequence 2-sequence 3; wherein, sequence 1 is preferably CAGATC, sequence 2 may be a sequence of 5-80 bases, such as 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75 bases, preferably a sequence of 10-50 bases, more preferably a sequence of 20-40 bases, and sequence 3 is preferably TGGATC.
More preferably, in the case where the delivery carrier carries two or more gene circuits, adjacent gene circuits are linked via sequence 4 or a sequence with more than 80% homology to sequence 4; wherein sequence 4 is
Sequence 4 and its homologous sequences are shown in Table 4 below.
Taking the combined use of “siRNA1” and “siRNA2” on the same delivery carrier as an example, the functional structural region of the delivery carrier can be expressed as (promoter-siRNA 1)-linker-(promoter-siRNA 2)-linker-(promoter-targeting tag), or (promoter-targeting tag-siRNA1)-linker-(promoter-targeting tag-siRNA2), or (promoter-siRNA1)-linker-(promoter-targeting tag-siRNA 2), etc.
More specifically, the functional structural region of the delivery carrier can be expressed as (5′-promoter-5′ flanking sequence-siRNA 1-loop sequence-compensation sequence-3′ flanking sequence)-linker-(5′-promoter-5′ flanking sequence-siRNA 2-loop sequence-compensation sequence-3′ flanking sequence)-linker-(5′-promoter-targeting tag), or (5′-promoter-targeting tag-5′ flanking sequence-siRNA 1-loop sequence-compensation sequence-3′ flanking sequence)-linker-(5′-promoter-targeting tag-5′ flanking sequence-siRNA 2-loop sequence-compensating sequence-3′ flanking sequence), or (5′-promoter-5′ flanking sequence-siRNA 1-loop sequence-compensation sequence-3′ flanking sequence)-linker-(5′-promoter-targeting tag-5′ flanking sequence-siRNA 2-loop sequence-compensation sequence-3′ flanking sequence), or (5′-promoter-targeting tag-5′ flanking sequence-siRNA 1-siRNA 2—loop sequence-compensation sequence-3′ flanking sequence), etc. Other situations can be deduced in this way and will not be repeated here. The above linker can be “sequence 1-sequence 2-sequence 3” or “sequence 4”, and a bracket indicates a complete gene circuit.
The delivery carrier described in this example can be a viral carrier or a non-viral carrier; wherein, viral carriers include adeno-associated viral vectors, adenoviral vectors, and retroviral vectors, and non-viral carrier include plasmid vectors, liposome carriers, cationic polymer carriers, nanoparticle carriers, and multifunctional envelope-type nano device.
Preferably, the delivery carrier is an adeno-associated viral vector or a plasmid vector. The adeno-associated viral vector is more preferably adeno-associated viral vector type 5, adeno-associated viral vector type 8 or adeno-associated viral vector type 9.
The delivery systems described above can be used in mammals including humans.
In order to construct the gene circuit and confirm its self-assembly and release, the following experiments were conducted:
First, referring to
For the core gene circuit construct, we designed a scheme that encodes an optimized siRNA expression backbone part under the control of a promoter part to maximize guide strand expression while minimizing undesired passenger strand expression, see
Next, we examined whether the core gene circuit directs the loading of siRNA into exosomes. HEK293T cells were transfected with the control scrambled circuit (CMV-scrR) or CMV-siRE circuit, and the exosomes in cell culture medium were characterized. Nanoparticle tracking analysis (NTA) revealed that similar amounts of exosomes were secreted in each group with similar size and distribution, peaking at 128-131 nm. Transmission electron microscopy (TEM) confirmed that the purified exosomes exhibited a typical round-shaped vesicular morphology and had correct size. Moreover, enrichment of specific exosome markers (CD63, TSG101 and CD9) was only detected in purified exosomes but not in cell culture medium. These results demonstrate that transfection with gene circuits did not affect the size, structure or number of exosomes generated by HEK293T cells. Finally, a significant amount of EGFR siRNA was detected in exosomes derived from HEK293T and Hepa 1-6 cells transfected with the CMV-siRE gene circuit, see
For the design of the targeting tag of the gene circuit, a sequence encoding a targeting tag fused to the N-terminus of Lamp2b (a canonical exosome membrane protein) was inserted downstream of the CMV promoter, see
Next, we examined whether the gene circuit enables the self-assembly of siRNAs into exosomes in vitro. HEK293T cells were transfected with a CMV-directed circuit encoding both EGFR and TNC siRNAs along with an RVG tag (CMV-RVG-siRE). The results showed that exosomes derived from the cell culture medium displayed typical morphology and size distribution, indicating that modification with the composable-core gene circuit did not alter the physical properties of exosomes. Moreover, a complete gene circuit encoding both EGFR and TNC siRNAs and a targeting tag (CMV-Flag-siRE) was constructed. Exosomes generated from the transfected HEK293T and hep 1-6 cells were successfully immunoprecipitated, and both EGFR and TNC siRNAs were abundantly present in the immunoprecipitated exosomes, see
Furthermore, AGO2 is widely expressed in organisms and is a core component of the RNA-induced silencing complex. It has endoribonuclease activity and can inhibit the expression of target genes by promoting the maturation of siRNA and regulating its biosynthesis and function.
Since siRNA processing is dependent on Argonaute 2 (AGO2) and the proper loading of siRNA into AGO2 is expected to enhance the on-target effects of siRNA, another immunoprecipitation experiment was performed to assess the association of AGO2 with siRNAs in exosomes. Experiments demonstrated that EGFR and TNC siRNAs were readily detected in the exosomes precipitated with anti-AGO2 antibody, suggesting that our design guarantees the loading of siRNA into the RNA-induced silencing complex (RISC) and facilitates the efficient transport of AGO2-bound siRNA into exosomes. Finally, to investigate whether the in vitro assembled siRNAs are functional, exosomes derived from HEK293T cells transfected with the CMV-RVG-siRE+T gene circuit were incubated with the U87MG glioblastoma cells. A dose-dependent downregulation of EGFR and TNC expression in U87MG cells was achieved, see
In short, the RNA delivery system provided in this example attaches the gene circuit to the delivery carrier to deliver it into the body, and the gene circuit are enriched in the host organ or tissue and self-assembled to form a complex. The RNA fragment that exerts the effect is then encapsulated and transported by the complex, with no immune responses, making it healthy and safe. In particular, the RNA fragment can also bind to AGO2 protein to improve delivery efficiency and gene suppression effects. This delivery system can deliver various kinds of small molecule RNA with high versatility. In addition, the preparation of the delivery carrier attached with the gene circuit is cheaper and simpler than the preparation of exosomes or proteins, polypeptides and other substances, and it also allows for the determination of a unified quality standard, enhances stability during using, and yields high economic benefits.
On the basis of Example 2, an RNA delivery system is provided in this example, and the delivery carrier used in the delivery system is a plasmid.
As shown in
CMV eGFP siRE gene circuit co-expressing eGFP protein and EGFR siRNA was injected intravenously into C57BL/6J mice. The results are shown in
The control plasmid (CMV-scrR) and the plasmid expressing EGFR siRNA (CMV-siRE) were injected into the mice respectively, and an in vitro model of mouse hepatocytes was established. The related siRNA levels in the hepatocyte exosomes of mice injected with CMV-scrR and CMV-siRE were respectively detected. The results are shown in
It is generally believed that binding to Ago2 protein is a necessary condition for siRNA to function, meaning that siRNA in exosomes can bind to Ago2 protein. Therefore, we performed Ago2 immunoprecipitation experiments, and the results are shown in
After intravenous injection of the plasmid into mice, the distribution of mature siRNA in different tissues is shown in
Mice were injected with control plasmid (CMV-scrR), 0.05 mg/kg CMV-siRE plasmid, 0.5 mg/kg CMV-siRE plasmid, and 5 mg/kg CMV-siRE plasmid, respectively, and the level of absolute siRNA (EGFR siRNA) was detected in the mouse liver, spleen, heart, lung, kidney, pancreas, brain, skeletal muscle, and CD4+ cells. The results are shown in
After the plasmid enters the body, it will express the precursor and then process it into a mature body (siRNA). Therefore, we detected the metabolism of the precursor and mature body (siRNA) in the liver of mice injected with the plasmid, and the result is shown in
After injecting exogenous siRNA into the common bile duct of mice, the levels of absolute siRNA in exosome-free plasma, exosomes, and plasma were detected respectively. The results are shown in
Mice were intravenously injected with siRNA with albumin ALB as promoter, siRNA with CMV as promoter, and siRNA without any promoter respectively. The absolute siRNA levels in mice were detected at 0 h, 3 h, 6 h, 9 h, 12 h, 24 h, 36 h, and 48 h after injection, and the results are shown in
We used fluorescence experiments to observe the inhibition of eGFP levels in mice by self-assembled eGFP siRNA. The process was as follows: eGFP transgenic mice were intravenously injected with PBS, or 5 mg/kg CMV-siRG or CMV-RVG-siRG plasmid, and treated for 24 h. The mice were then sacrificed, and their eGFP fluorescence levels were detected in frozen sections.
The alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), blood urea nitrogen (BUN), serum alkaline phosphatase (ALP), creatinine (CREA) contents, thymus weight, spleen weight, and percentage in peripheral blood cells were detected in mice injected with PBS, CMV-scrR, and CMV-siRE respectively. The results are shown in
The results showed that mice injected with PBS, CMV-scrR, and CMV-siRE had almost the same ALT, AST contents, thymus weight, spleen weight, and percentage in peripheral blood cells. Compared with mice injected with PBS, mice injected with CMV-siRE also had no tissue damage in the liver, lung, spleen, and kidney.
Therefore, the RNA delivery system provided in this example uses a plasmid as a carrier, and as a mature injection, the plasmid has safety and reliability that have been fully verified, and has a very good druggability. The RNA sequence that exerts the final effect is encapsulated and transported by endogenous exosomes, with no immune responses, and there is no need to verify the safety of the exosomes. The delivery system can deliver all kinds of small molecule RNAs and has strong versatility. Moreover, the preparation of plasmids is much cheaper than the preparation of exosomes, proteins, polypeptides and the like, with good economy. The RNA delivery system provided in this example can tightly bind to AGO 2 and be enriched into a complex (exosomes) after self-assembly in vivo, which not only prevents its premature degradation and maintains its stability in circulation, but also facilitates receptor cell absorption, intracytoplasmic release and lysosomal escape, and only a low dose is required.
On the basis of Example 2, an RNA delivery system is provided in this example, and the delivery carrier used in the delivery system is a virus. The virus can carry the gene circuit as described in Example 1, and can be enriched in the host organ or tissue and endogenously spontaneously form a complex comprising the RNA fragment and having a target structure in the host organ or tissue. The complex seeks for and binds to the target organ or tissue through the targeting tag, and delivers the RNA fragment into the target organ or tissue.
The viral vector-based RNA delivery system provided in this example uses a virus as a carrier, and as a mature injection, the virus has safety and reliability that have been fully verified, and has a very good druggability. The RNA sequence that exerts the final effect is encapsulated and transported by endogenous exosomes, with no immune responses, and there is no need to verify the safety of the exosomes. The delivery system can deliver all kinds of small molecule RNAs and has strong versatility. Moreover, the preparation of viral vectors is much cheaper than the preparation of exosomes, proteins, polypeptides and the like, with good economy. The viral vector-based RNA delivery system provided in this example can tightly bind to AGO2 and be enriched into a complex (exosomes) after self-assembly in vivo, which not only prevents its premature degradation and maintains its stability in circulation, but also facilitates receptor cell absorption, intracytoplasmic release and lysosomal escape, and only a low dose is required.
On the basis of Examples 1-2, a medicament is provided in this example. The medicament comprises a delivery carrier carrying the gene circuit as described in Example 1, and the delivery carrier can be enriched in the host organ or tissue and endogenously spontaneously form a complex comprising the RNA fragment and having a target structure in the host organ or tissue. The complex seeks for and binds to the target organ or tissue through the targeting tag, and delivers the RNA fragment into the target organ or tissue.
The medicament can enter the human body by oral administration, inhalation, subcutaneous injection, intramuscular injection or intravenous injection, and then be delivered to the target tissue through the RNA delivery system described in Example 2 to exert a therapeutic effect.
The medicament can be used to treat cancer, pulmonary fibrosis, colitis, obesity, cardiovascular disease caused by obesity, type 2 diabetes, Huntington's disease, Parkinson's disease, myasthenia gravis, Alzheimer's disease, graft-versus-host disease and related diseases.
The medicament in this example may also comprise a pharmaceutically acceptable carrier, which includes but is not limited to diluents, buffers, emulsions, encapsulating agents, excipients, fillers, adhesives, sprays, transdermal absorption agents, wetting agents, disintegrants, absorption accelerators, surfactants, colorants, flavoring agents, adjuvants, desiccants, adsorption carriers, etc.
The dosage form of the medicament provided in this example may be tablets, capsules, powders, granules, pills, suppositories, ointments, solutions, suspensions, lotions, gels, pastes, etc.
For explanations of the delivery carrier, gene circuit, targeting tag, etc. in the medicament, please refer to Example 1 and Example 2, and will not be repeated here.
The use of the RNA delivery system provided in this example in the medicament offers a platform of drug delivery that facilitates the establishment of further foundations for RNA drug research and development. This significantly advances the development and utilization of RNA drugs.
On the basis of Example 3, use of an RNA delivery system in the manufacture of a medicament for treating a disease is provided in this example. The delivery carrier used in the RNA delivery system is a plasmid, and the medicament is used for treating lung cancer. Here, it will be specifically described by the following experiments.
As shown in
As shown in
As shown in
As shown in
As shown in
As shown in
In summary, CMV-siRE had a significant therapeutic effect on EGFR-mutated lung cancer tumors.
HE staining and immunohistochemical staining were performed on mice injected with PBS buffer/CMV-scrR/gefitinib/CMV-siRE respectively. The results are shown in
As shown in
As shown in
As shown in
As shown in
As shown in
As shown in
As shown in
In summary, CMV-siRK had a significant therapeutic effect on KRAS-mutated lung cancer tumors.
HE staining and immunohistochemical staining were performed on mice injected with CMV-scrR/CMV-siRK. The results are shown in
On the basis of Example 4, use of an RNA delivery system in the manufacture of a medicament for treating a disease is provided in this example. The delivery carrier used in the RNA delivery system is a virus, and the medicament is used for treating lung cancer. This example will specifically illustrate the effect of the viral vector-based RNA delivery system in the treatment of lung cancer through the following four experiments.
In the first experiment, we used AAV-5 adeno-associated virus with high affinity for the liver to encapsulate the EGFR siRNA system (AAV-CMV-EGFR siRNA) and the KRAS siRNA system (AAV-CMV-KRAS siRNA). Mice were injected with 100 μL of AAV solution with a titer of 1012 V. g/ml through the tail vein. The in vivo expression of the AAV system was monitored by small animal in vivo imaging. After 3 weeks, it was found that the AAV system was stably expressed in the body, especially in the liver.
In the second experiment, one experimental group and two control groups were set up, wherein the experimental group was the AAV-CMV-KRAS-siRNA group, and the control groups were the PBS group and the AAV-CMV-scrR group.
The same number of mice were selected from each group. Mouse lung cancer cells (LLC cells) were injected into the mice, and CT scanning technology was used to observe the progress of mouse model establishment. After 30 days, the successfully established mice were administered once every two days. Specifically, mice in the PBS group/AAV-CMV-scrR group/AAV-CMV-KRAS siRNA group were injected with PBS buffer/AAV-CMV-scrR/AAV-CMV-KRAS siRNA once every two days for treatment. Survival analysis and tumor evaluation were performed on the mice. Treatment was stopped after 7 administrations.
The survival of mice in each group was counted within 100 days after treatment, and the results are shown in
CT scanning was performed on mice in each group before and after administration. 3D modeling of mouse lung tissue was performed based on the CT images, and the tumor volume was calculated. The results are shown in
The expression levels of KRAS protein and mRNA in the lung of mice in each group were detected by RT-qPCR and Western blotting, respectively, and the results are shown in
The above experiments show that AAV-CMV-KRAS siRNA had a significant therapeutic effect on lung cancer tumors in mice.
In the third experiment, one experimental group and two control groups were set up, wherein the experimental group was the AAV-CMV-EGFR-siRNA group, and the control groups were the PBS group and the AAV-CMV-scrR group.
EGFR-DEL19 mouse model was constructed and fed with doxycycline feed to induce tumor occurrence. After 30 days, the successfully constructed mice were administered once every two days. Specifically, mice in the PBS group/AAV-CMV-scrR group/AAV-CMV-EGFR siRNA group were injected with PBS buffer/AAV-CMV-scrR/AAV-CMV-EGFR siRNA once every two days for treatment. Survival analysis and tumor evaluation were performed on the mice. Treatment was stopped after 7 administrations.
The survival of mice in each group was counted within 100 days after treatment, and the results are shown in
CT scanning was performed on mice in each group before and after administration, and the CT images are shown in
The expression levels of EGFR protein and mRNA in the lung of mice in each group were detected by RT-qPCR and Western blotting, respectively, and the results are shown in
The above experiments show that AAV-CMV-EGFR siRNA had a significant therapeutic effect on EGFR-mutated lung cancer tumors in mice.
In the fourth experiment, two experimental groups and two control groups were set up, wherein the experimental groups were the AAV-CMV-KRAS-siRNA group the AAV-CMV-EGFR-siRNA group, and the control groups were the PBS group and the AAV-CMV-scrR group.
EGFR-DEL19 mouse model was constructed and fed with doxycycline feed to induce tumor occurrence. After 30 days, the successfully constructed mice were administered once every two days. Specifically, mice in the PBS group/AAV-CMV-scrR group/AAV-CMV-EGFR siRNA group/AAV-CMV-KRAS siRNA group were injected with PBS buffer/AAV-CMV-scrR/AAV-CMV-EGFR siRNA/AAV-CMV-KRAS siRNA once every two days for treatment.
After treatment, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), serum alkaline phosphatase (ALP), creatinine (CREA) and blood urea nitrogen (BUN) were detected in each group of mice, and the results are shown in
The above experiments demonstrate that the EGFR siRNA system (AAV-CMV-EGFR siRNA) and KRAS siRNA system (AAV-CMV-KRAS siRNA) encapsulated with AAV-5 type adeno-associated virus with high affinity for the liver is safe and reliable and will not produce negative effects, which is suitable for large-scale promotion and application.
On the basis of Example 3, use of an RNA delivery system in the manufacture of a medicament for treating a disease is provided in this example. The delivery carrier used in the RNA delivery system is a plasmid, and the medicament is used for treating kidney cancer. This is illustrated in detail through the following experiments.
Different mice were injected with PBS buffer/control plasmid/VEGFR siRNA plasmid/mTOR siRNA plasmid/MIX siRNA plasmid (combined use of VEGFR siRNA and mTOR siRNA)/sunitinib/everolimus. The development of kidney cancer tumors in mice was observed, and the results are shown in
In summary, the combined use of VEGFR siRNA and mTOR siRNA had a significant therapeutic effect on kidney cancer tumors.
On the basis of Example 3, use of an RNA delivery system in the manufacture of a medicament for treating a disease is provided in this example. The delivery carrier used in the RNA delivery system is a plasmid, and the medicament is used for treating colitis. This example will specifically illustrate the effect of the RNA delivery system in the treatment of colitis through the following two experiments.
In the first experiment, we set up 3 experimental groups and 3 control groups. The experimental groups were anti-TNF-α (0.5) group, anti-TNF-α (5) group and anti-TNF-α (20) group; and the control groups were mock group, scr-RNA group and IFX group.
Among them, the anti-TNF-α (0.5) group, anti-TNF-α (5) group, and anti-TNF-α (20) group respectively used plasmids to encapsulate the TNF-α siRNA gene circuit (CMV-siRTNF-α). 0.5 μL, 5 μL, and 20 μL of CMV-siRTNF-α solutions were injected into the mice through the tail vein.
The mock group was the negative control group, and the scr-RNA group and IFX group were injected with scr-RNA plasmid and IFX (infliximab) through the tail vein of mice respectively.
DSS-induced chronic colitis model was then constructed, during which weights were recorded every day. The results are shown in
After the model was constructed, the in vivo expression of the plasmid system was monitored by small animal in vivo imaging, and then the mice were sacrificed for observation of the colon. The results are shown in
The disease activity index of the mice was evaluated, and the results are shown in
TNF-α mRNA was detected in mouse colon, and the results are shown in
HE staining of mouse colon sections and pathological score statistics were performed, and the results are shown in
The above experiments can prove that the use of plasmid-encapsulated TNF-α siRNA system treatment was more effective than IFX in improving the manifestations of colitis.
In the second experiment, we set up 4 experimental groups and 3 control groups. The experimental groups were anti-TNF-α group, anti-integrin-α group, anti-B7 group, and anti-mix group. The control groups were mock group, PBS group, and scr-RNA group.
The anti-TNF-α group, anti-integrin-α group, anti-B7 group, and anti-mix group used plasmids to encapsulate the TNF-α siRNA gene circuit (CMV-siRTNF-α), integrin-α siRNA gene circuit (CMV-siRintegrin-α), B7 siRNA gene circuit (CMV-siRB7), mix siRNA gene circuit (CMV-siRmix, i.e., CMV-siRTNF-α+integrin-α+B7). 20 μL was injected into the mice through tail vein, and the expression of the system was monitored in vivo in small animals. It can be seen that the above system was stably expressed in vivo, especially in the liver.
The mock group was the negative control group, and mice in the scr-RNA group and PBS group were injected with scr-RNA plasmid and PBS solution (phosphate buffered saline solution) through the tail vein, respectively.
DSS-induced chronic colitis model was then constructed, during which weights were recorded every day. The results are shown in
After the model construction was completed, the in vivo expression of the plasmid system was monitored by small animal in vivo imaging, and then the mice were sacrificed for observation of the colon. The results are shown in
The disease activity index of mice was evaluated, and the results are shown in
TNF-α mRNA, integrin mRNA and B7 mRNA were detected in mouse plasma, liver and colon. The results are shown in
HE staining was performed on mouse colon sections. The results are shown in
The above experiments show that the use of the plasmid with high affinity for the liver to encapsulate the CMV-siRTNF-α+integrin-α+B7 gene circuit can achieve long-term expression of TNF-α mRNA, B7 mRNA and integrin mRNA and multiple target gene silencing, and can significantly alleviate the degree of colonic inflammation, with great drug potential and clinical research value.
On the basis of Example 4, use of an RNA delivery system in the manufacture of a medicament for treating a disease is provided in this example. The delivery carrier used in the RNA delivery system is a virus, and the medicament is used for treating colitis. This example will specifically illustrate the effect of the viral vector-based RNA delivery system in the treatment of colitis through the following two experiments.
In the first experiment, we set up 3 experimental groups and 2 control groups. The experimental groups were AAV-CMV-siRTNF-α (low) group, AAV-CMV-siRTNF-α (medium) group, and AAV-CMV-siRTNF-α (high) group; and the control groups were Normal group and AAV-CMV-scrR group.
The experimental protocol is shown in
The in vivo expression of the AAV system was monitored by small animal in vivo imaging. The results are shown in
DSS-induced chronic colitis model was then constructed, during which weights was recorded every two days. The results are shown in
At the end of the tenth week of model construction, the in vivo expression of the AAV system was monitored by small animal in vivo imaging, and then the mice were sacrificed for observation of the colon. The results are shown in
The disease index of mice in each group was scored and counted, and the results are shown in
The levels of TNF-α siRNA in mice of each group were detected, and the results are shown in
The levels of TNF-α mRNA in mice of each group were detected, and the results are shown in
The pro-inflammatory cytokines IL-6, IL-12 and IL-23 in the mouse colon were detected, and the results are shown in
HE staining and pathological scoring statistics were performed on mouse colon sections, and the results are shown in
The above experiments show that the use of AAV with high affinity for the liver to encapsulate the CMV-siRTNF-α gene circuit can achieve long-term expression of TNF-α siRNA and long-term TNF-α silencing, and can alleviate colitis to a certain extent, with great drug potential and clinical research value.
In the second experiment, we set up three experimental groups and two control groups. Wherein, the experimental groups were AAV-CMV-siRT+B+I (low) group, AAV-CMV-siRT+B+I (medium) group, and AAV-CMV-siRT+B+I (high) group; and the control groups were Normal group and AAV-CMV-scrR group.
The AAV-CMV-siRT+B+I (low) group, AAV-CMV-siRT+B+I (medium) group, and AAV-CMV-siRT+B+I (high) group used AAV-5 type adeno-associated virus with high affinity for the liver to encapsulate the TNF-α siRNA, B7-siRNA and Integrin α4 siRNA element tandem drug delivery system (AAV-CMV-siRT+B+I). Mice were injected with 25 μL, 50 μL and 100 μL of AAV solution with a titer of 1012 V. g/ml through the tail vein.
The in vivo expression of the AAV system was monitored by small animal in vivo imaging. The results are shown in
DSS-induced chronic colitis model was then constructed, during which weights was recorded every two days. The results are shown in
At the end of the tenth week of model construction, the in vivo expression of the AAV system was monitored by small animal in vivo imaging, and then the mice were sacrificed for observation of the colon. The results are shown in
The disease index of mice in each group was scored and counted, and the results are shown in
The levels of TNF-α siRNA, B7 siRNA and integrin α4 siRNA were detected in mouse plasma, and the results are shown in
The levels of TNF-α siRNA, B7 siRNA and integrin α4 siRNA were detected in mouse liver, and the results are shown in
The levels of TNF-α siRNA, B7 siRNA and integrin α4 siRNA were detected in mouse colon, and the results are shown in
The levels of TNF-α mRNA, B7 mRNA and integrin α4 mRNA were detected in mouse colon, and the results are shown in
HE staining and pathological scoring statistics were performed on mouse colon sections, and the results are shown in
The above experiments show that the use of AAV with high affinity for the liver to encapsulate the CMV-siRT+B+I gene circuit can achieve long-term expression of TNF-α siRNA, B7 siRNA and integrinα4 siRNA and multiple target gene silencing, and can significantly alleviate the degree of colon inflammation, with great drug potential and clinical research value.
On the basis of Example 3, use of an RNA delivery system in the manufacture of a medicament for treating a disease is provided in this example. The delivery carrier used in the RNA delivery system is a plasmid, and the medicament is used for treating pulmonary fibrosis. This example will specifically illustrate the use of the RNA delivery system in the treatment of pulmonary fibrosis through the following experiments.
In this example, 8 experimental groups and 3 control groups were set up. The experimental groups were Anti-miR-21 (1 mg/kg) group, Anti-miR-21 (5 mg/kg) group, Anti-miR-21 (10 mg/kg) group, TGF-β1 siRNA (1 mg/kg) group, TGF-β1 siRNA (5 mg/kg) group, TGF-β1 siRNA (10 mg/kg) group, Anti-miR-21+TGF-β1 siRNA (10 mg/kg) group, Pirfenidone (300 mg/kg) group; and the control group were Normal group, PBS group and scrRNA group.
Among them, mice with pulmonary fibrosis in the Anti-miR-21 (1 mg/kg) group, Anti-miR-21 (5 mg/kg) group, and Anti-miR-21 (10 mg/kg) group were injected into the tail vein with 1 mg/kg, 5 mg/kg, 10 mg/kg of the plasmid carrying Anti-miR-21 (antisense strand of miRNA 21); mice with pulmonary fibrosis in TGF-β1 siRNA (1 mg/kg) group, TGF-β1 siRNA (5 mg/kg) group, TGF-β1 siRNA (10 mg/kg) group were injected into the tail vein with 1 mg/kg, 5 mg/kg, 10 mg/kg of TGF-β1 siRNA plasmid; mice with pulmonary fibrosis in Anti-miR-21+TGF-β1 siRNA (10 mg/kg) group were injected into the tail vein with 10 mg/kg Anti-miR-21 and TGF-β1 siRNA plasmids; and mice with pulmonary fibrosis in Pirfenidone (300 mg/kg) group was injected into the tail vein with 300 mg/kg Pirfenidone. The Normal group was the normal control group, and mice with pulmonary fibrosis in the PBS group and the scrRNA group were injected into the tail vein with PBS solution and control plasmid, respectively.
The hydroxyproline content of mice in each group was detected respectively, and the results are shown in
Fluorescent staining was performed on the lung of mice in each group, and the results are shown in
Masson's trichrome staining was performed on the lung of mice in each group, and the results are shown in
H&E staining was performed on the lung of mice in each group, and the results are shown in
The TGF-β1 protein level and TGF-β1 mRNA level were detected in mice in the Normal group, PBS group, scrRNA group, TGF-β1 siRNA (1 mg/kg) group, TGF-β1 siRNA (5 mg/kg) group, TGF-β1 siRNA (10 mg/kg) group, and Pirfenidone (300 mg/kg) by western blot, and the results are shown in
The relative miR-21 level was detected in mice in the Normal group, PBS group, scrRNA group, Anti-miR-21 (1 mg/kg) group, Anti-miR-21 (5 mg/kg) group, and Anti-miR-21 (10 mg/kg) group, and the results are shown in
The above experiments show that the use of the plasmid with high affinity for the liver to encapsulate the CMV-siRmiR-21, CMV-siRTGF-β1, and CMV-siRmiR-21+TGF-β1 gene circuits can significantly alleviate the degree of pulmonary fibrosis, with great drug potential and clinical research value.
On the basis of Example 4, use of an RNA delivery system in the manufacture of a medicament for treating a disease is provided in this example. The delivery carrier used in the RNA delivery system is a virus, and the medicament is used for treating pulmonary fibrosis. This example will specifically illustrate the effect of the viral vector-based RNA delivery system in the treatment of pulmonary fibrosis through the following experiments.
In this example, AAV-5 type adeno-associated virus with high affinity for the liver was used to encapsulate anti-miR-21/TGF-β1 siRNA/anti-miR-21+TGF-β1 siRNA system to obtain AAV-anti-miR21/AAV-TGF-β1 siRNA/AAV-MIX, respectively. Mice were injected with 100 μL of AAV solution with a titer of 1012 V. g/ml through the tail vein. The in vivo expression of the AAV system was monitored by small animal in vivo imaging, and after 3 weeks, the AAV system was stably expressed in the body, especially in the liver.
Mice were then selected for modeling. After the modeling was successful, PB S buffer/AAV-scrR/AAV-anti-miR21/AAV-TGF-β1 siRNA/AAV-MIX (10 mg/kg) was injected into mice to obtain PBS group/AAV-scrR group/AAV-anti-miR21 group/AAV-TGF-β1 siRNA group/AAV-MIX group, respectively.
The relative TGF-β1 mRNA level was detected in mice in the Normal group, PBS group, AAV-scrR group, and AAV-TGF-β1 siRNA group, and the results are shown in
The relative miR21 mRNA level was detected in mice in the Normal group, PBS group, AAV-scrR group, and AAV-anti-miR21 group, and the results are shown in
Hydroxyproline is the main component of collagen, and its content reflects the degree of pulmonary fibrosis. The hydroxyproline content of mice in each group was detected, and the results are shown in
On the basis of Example 3, use of an RNA delivery system in the manufacture of a medicament for treating a disease is provided in this example. The delivery carrier used in the RNA delivery system is a plasmid, and the medicament is used for treating glioblastoma. This example will specifically illustrate the use of the RNA delivery system in the treatment of glioblastoma through the following experiments.
In the first experiment, we set up 5 experimental groups and 3 control groups. The experimental groups were CMV-siRE group, CMV-siRT group, CMV-RVG-siRE+T group, CMV-siRE+T group, CMV-Flag-siRE+T group, where “E” represents EGFR, “T” represents TNC, and the control groups were PBS group, CMV-scrR group, and CMV-Flag-scrR group. The specific experimental protocol is shown in
The expression levels of CD63 protein and siRNA of mice in each group were detected. The results are shown in
In the second experiment, we set up 2 experimental groups and 2 control groups. The experimental groups were CMV-RVG-siRE group and CMV-RVG-siRE+T group, and the control groups were PBS group and CMV-scrR group.
The specific experimental protocol is shown in
As shown in
As shown in
As shown in
As shown in
As shown in
The above experimental data demonstrate that intravenous injection of CMV-RVG-siRE+T plasmid can deliver siRNA to the brain and inhibit the growth of glioblastoma.
The brains of mice in each group were subjected to immunohistochemical staining, and the proportion of EGFR, TNC, and PCNA staining in each visual field was counted. The results are shown in
On the basis of Example 4, use of an RNA delivery system in the manufacture of a medicament for treating a disease is provided in this example. The delivery carrier used in the RNA delivery system is a virus, and the medicament is used for treating glioblastoma. This example will specifically illustrate the effect of the viral vector-based RNA delivery system in the treatment of glioblastoma through the following experiments.
In this example, AAV-5 type adeno-associated virus with high affinity for the liver was used to encapsulate the EGFR siRNA system (AAV-CMV-RVG-siRE) and the EGFR siRNA and TNC siRNA system (AAV-CMV-RVG-siRE+T). Mice were injected with 100 μL of AAV solution with a titer of 1012 V. g/ml through the tail vein. The in vivo expression of the AAV system was monitored by small animal in vivo imaging, and after 3 weeks, the AAV system was stably expressed in the body, especially in the liver.
Mice were selected and injected with glioblastoma cells (U-87 MG-Luc cells). From the 7th day to the 21st day, mice were injected with PBS buffer/AAV-CMV-scrR/AAV-CMV-RVG-siRE/AAV-CMV-RVG-siRE+T (5 mg/kg) every two days for treatment, to obtain PBS group/AAV-scrR group/AAV-CMV-RVG-siRE group/AAV-CMV-RVG-siRE+T group, respectively.
Survival analysis was performed on mice in each group, and the survival rate of mice in each group was counted at 20 days, 40 days, 60 days, and 80 days after receiving treatment. The results are shown in
Tumor evaluation was performed on mice in each group. Specifically, BLI in vivo imaging was performed on mice on days 7, 14, 28, and 35. The results are shown in
On the basis of Example 3, use of an RNA delivery system in the manufacture of a medicament for treating a disease is provided in this example. The delivery carrier used in the RNA delivery system is a plasmid, and the medicament is used for treating obesity. This example will specifically illustrate the use of the RNA delivery system in the treatment of obesity through the following two experiments.
In the first experiment, 2 experimental groups and 1 control group were set up. The experimental groups were CMV-siRP group and CMV-RVG-siRP group, and the control group was CMV-scrR group, where “P” means PTP1B.
Mice in the CMV-siRP group, CMV-RVG-siRP group, and CMV-scrR group were injected with 5 mg/kg CMV-siRP plasmid, CMV-RVG-siRP plasmid, and CMV-scrR plasmid respectively, and then fluorescence microscope images of the hypothalamus and liver of mice in each group were obtained respectively. The results are shown in
In the second experiment, 2 experimental groups and 2 control groups were set up. The experimental groups were CMV-siRP group and CMV-RVG-siRP group, and the control groups were PBS group and CMV-scrR group.
The specific experimental protocol is shown in
As shown in
As shown in
The oxygen consumption, respiratory exchange ratio, activity volume, and heat production of differently treated mice were continuously detected for 72 h using metabolic cages, and then the average values were drawn for statistical analysis. The results are shown in
As shown in
As shown in
As shown in
As shown in
As shown in
As shown in
From the above experiments, it can be concluded that intravenous injection of CMV-RVG-siRP plasmid can reduce obesity in obese mouse models.
The serum total cholesterol (TC), triglycerides (TG), and low-density lipoprotein (LDL) of mice in each group were measured, and the results are shown in
The body length of mice in each group was measured, and the results are shown in
The HFD food intake of mice in each group was counted, and the results are shown in
The liver tissue of mice in each group was collected after treatment and compared with the normal control. The results are shown in
The above experiments show that intravenous injection of CMV-RVG-siRP plasmid can reduce fatty liver in obese mice.
On the basis of Example 4, use of an RNA delivery system in the manufacture of a medicament for treating a disease is provided in this example. The delivery carrier used in the RNA delivery system is a virus, and the medicament is used for treating obesity. This example will specifically illustrate the effect of the viral vector-based RNA delivery system in the treatment of obesity through the following experiments.
AAV-5 type adeno-associated virus with high affinity for the liver was used to encapsulate the PTP1B siRNA system (AAV-CMV-siRP/AAV-CMV-RVG-siRP). Mice were injected with 100 μL of AAV solution with a titer of 1012 V. g/ml through the tail vein. The in vivo expression of the AAV system was monitored by small animal in vivo imaging, and after 3 weeks, the AAV system was stably expressed in the body, especially in the liver.
C57BL/6 mice were selected and injected with PBS buffer/AAV-CMV-scrR/AAV-CMV-siR P/AAV-CMV-RVG-siRP 12 weeks later, and once every two days for 24 days to obtain PBS group/AAV-CMV-scrR group/AAV-CMV-siRP group/AAV-CMV-RVG-siRP group, respectively. The changes in body weight, weight of epididymal fat pads, initial food intake, serum leptin content, blood sugar content, basal glucose content, serum total cholesterol (TC), triglyceride (TG), low-density lipoprotein protein (LDL), body length, and food intake of mice in each group were detected and counted. The results are as follows.
As shown in
As shown in
As shown in
As shown in
As shown in
As shown in
As shown in
As shown in
As shown in
The above experiments can demonstrate that AAV-CMV-siRP and AAV-CMV-RVG-siRP had a certain degree of inhibitory effect on obesity.
On the basis of Example 3, use of an RNA delivery system in the manufacture of a medicament for treating a disease is provided in this example. The delivery carrier used in the RNA delivery system is a plasmid, and the medicament is used for treating Huntington's disease. This example will specifically illustrate the use of the RNA delivery system in the treatment of Huntington's disease through the following five experiments.
In the first experiment, 2 experimental groups and 2 control groups were set up. The experimental groups were CMV-siR mHTT group and CMV-RVG-siRmHTT group, and the control groups were PBS group and CMV-scrR group.
The experimental protocol is shown in
As shown in
After injecting plasmid/solution into mice in each group, plasma exosomes were extracted, labeled with PKH26, co-cultured with cells and photographed using a confocal microscope. The results are shown in
After co-culturing the extracted plasma exosomes from mice in each group with cells, the changes in HTT protein levels and mRNA levels of mice in each group were detected. As shown in
After co-culturing the extracted plasma exosomes from mice in each group with cells, the aggregation of HTT protein of mice in each group was observed and counted. As shown in
The absolute siRNA expression levels in the liver, plasma, cortex, and striatum of mice in each group were detected respectively. As shown in
As shown in
In the second experiment, 2 experimental groups and 2 control groups were set up. The experimental groups were CMV-siRGFP group and CMV-RVG-siRGFP group, and the control groups were PBS group and CMV-scrR group. GFP transgenic mice in the CMV-siRGFP group, CMV-RVG-siR′ group, PBS group, and CMV-scrR group were injected with CMV-siRGFP plasmid, CMV-RVG-siR′ plasmid, PBS solution, and CMV-scrR plasmid through the tail vein, respectively.
As shown in
In the third experiment, two experimental groups and one control group were set up. The experimental groups were CMV-siR mHTT group and CMV-RVG-siRmHTT group, and the control group was CMV-scrR group.
The experimental protocol is shown in
As shown in
As shown in
In the fourth experiment, one experimental group and one control group were set up. The experimental group was CMV-RVG-siRmHTT group, and the control group was CMV-scrR group.
The experimental protocol is shown in
As shown in
As shown in
As shown in
The above experiments demonstrate that intravenous injection of CMV-RVG-siR′ T plasmid helps suppress mHTT in the striatum and cortex, thereby improving exercise capacity and alleviating neuropathology in HD mice.
In the fifth experiment, one experimental group and one control group were set up. The experimental group was the CMV-RVG-siRmHTT group, and the control group was the CMV-scrR group.
The experimental protocol is shown in
As shown in
As shown in
As shown in
As shown in
The above experiments can demonstrate that intravenous injection of CMV-RVG-siRmHTT plasmid can help reduce mHTT protein and toxic aggregates in the striatum and cortex, thereby improving behavioral defects and neuropathology in the striatum and cortex.
On the basis of Example 4, use of an RNA delivery system in the manufacture of a medicament for treating a disease is provided in this example. The delivery carrier used in the RNA delivery system is a virus, and the medicament is used for treating Huntington's disease. This example will specifically illustrate the effect of the viral vector-based RNA delivery system in the treatment of Huntington's disease through the following experiments.
In this example, AAV-5 type adeno-associated virus with high affinity for the liver was used to encapsulate the HTT siRNA system (AAV-CMV-siRmHTT/AAV-CMV-RVG-siRmHTT). Mice were injected with 100 μL of AAV solution with a titer of 1012 V. g/ml through the tail vein. The in vivo expression of the AAV system was monitored by small animal in vivo imaging, and after 3 weeks, the AAV system was stably expressed in the body, especially in the liver.
Mice were then selected for modeling. After the completion of modeling, mice were injected with PBS buffer/AAV-CMV-scrR/AAV-CMV-siRmHTT/AAV-CMV-RVG-siRmHTT to obtain PBS group/AAV-CMV-scrR group/AAV-CMV-siRmHTT group/AAV-CMV-RVG-siRmHTT group. After the above solution was injected into the tail vein, the plasma exosomes were isolated, labeled with PKH26 dye, and co-cultured with cells to observe the absorption of exosomes by cells. The results are as follows.
As shown in
As shown in
As shown in
As shown in
As shown in
As shown in
The above experiments can demonstrate that intravenous injection of AAV-CMV-RVG-SiRmHTT can help reduce mHTT protein and toxic aggregates in the striatum and cortex, thereby exerting a therapeutic effect on Huntington's disease.
On the basis of Example 3, use of an RNA delivery system in the manufacture of a medicament for treating a disease is provided in this example. The delivery carrier used in the RNA delivery system is a plasmid, and the medicament is used for treating Parkinson's disease. This example will specifically illustrate the use of the RNA delivery system in the treatment of Parkinson's disease through the following experiments.
In this experiment, LRRK2R1441G transgenic mice were selected for the experiment when they were 3 months old, and an LPS intervention group and an LPS non-intervention group were set up. The LPS intervention group was treated with CMV-scrR/CMV-RVG-siRLRRK2 7 days after LPS intervention.
As shown in
As shown in
As shown in
The above experiments can demonstrate that intravenous injection of CMV-RVG-siRLRRK2 plasmid helps suppress LRRK2 in dopaminergic neurons, thereby reducing the development of neuropathology in mice with Parkinson's disease.
To further investigate this critical issue and elucidate the pharmacokinetics and pharmacodynamics of self-assembled siRNA in vivo using plasmids as delivery carrier, we conducted a more detailed study in Macaca fascicularis, a well-known non-human primate model used in safety assessment studies. With ethical approval, we used 4 adult macaques for intravenous injection of 5 mg/kg CMV-siRE plasmid, and blood samples were collected before injection or at different time points after injection. One month later, these macaques were intravenously injected with 5 mg/kg CMV-siRE plasmid daily for a total of 5 times, and blood samples were collected before injection or at different time points after the last injection.
As shown in
The above experiments can show that CMV-siRE plasmid can be safe and effective for primates such as Macaca fascicularis, with broad application prospects.
Although the RNA delivery system provided by this application can self-assemble the gene circuit comprising the RNA fragment in the liver to form exosomes that can encapsulate and protect the RNA fragment, the safety and stability of the RNA fragment need to be considered during the transportation from outside the body to the liver, so we conducted the following experiments.
In this example, the control group and experimental groups 1-5 were set up. The same number of C57BL/6J mice were selected in each group, and mice were intravenously injected with EGFR siRNA plasmid (0.5 mg/kg). Among them, the EGFR siRNA used in the control group had any modification; the EGFR siRNA used in experimental group 1 was obtained by phosphorothioate modification (replacing the non-bridging oxygen atom of the phosphodiester bond with a sulfur atom); the EGFR siRNA used in experimental group 2 was obtained by 2′ oxymethyl modification (modifying the 2′-hydroxyl group of the pentose nucleotide and introducing a methyl group at this position); the EGFR siRNA used in experimental group 3 was obtained by 5′ bromouracil modification (introducing bromine at the 5 position of uracil); the EGFR siRNA used in experimental group 4 was obtained by hydrophobic substituent modification (so that the siRNA contained a triazole backbone unit with a pyrimidine-modified hydrophobic substituent); and the EGFR siRNA used in experimental group 5 was obtained by 2′ fluoropyrimidine modification (replacing the 2′-OH of the pyrimidine nucleotide on the siRNA with 2′-F).
The levels of EGFR siRNA in the liver, lung, brain, kidney, and CD4+ cells of mice in each group were detected respectively, and the results are shown in
The above results show that although the EGFR siRNA was chemically modified in the experimental groups 1-5, the stability of the siRNA obtained by the modification method used in the experimental groups 1-4 was not significantly improved.
However, the expression of siRNA obtained by using 2′ fluoropyrimidine modification in experimental group 5 was significantly improved in various tissues and organs, and it achieved the best effect. Therefore, 2′ fluoropyrimidine modification can greatly improve the stability of RNA during delivery.
The terms “upper”, “lower”, “front”, “back”, “left”, “right”, etc. used herein are only used to express the relative positional relationship between related parts, but not to limit the absolute position of these related parts.
The terms “first”, “second”, etc. used herein are only used to distinguish each other, but do not indicate the degree of importance, order, or the prerequisite for each other's existence.
The terms “equal”, “identical”, etc. used herein are not limitations in a strict mathematical and/or geometric sense, but also include errors that are understandable by those skilled in the art and allowed in manufacturing or use.
Unless otherwise stated, numerical ranges herein include not only the entire range within both endpoints, but also several subranges subsumed therein.
The preferred specific embodiments and examples of the present application have been described in detail above in conjunction with the accompanying drawings. However, the present application is not limited to the above-mentioned embodiments and examples. Within the scope of knowledge possessed by those skilled in the art, various changes can be made without departing from the concept of the present application.
| Number | Date | Country | Kind |
|---|---|---|---|
| 202110336983.6 | Mar 2021 | CN | national |
This application is a continuation application of International Application No. PCT/CN2022/083591, filed Mar. 29, 2022, which application claims priority to Chinese Application No. CN202110336983.6, filed Mar. 29, 2021, the disclosure of which are incorporated herein by reference in their entirety.
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/CN2022/083591 | Mar 2022 | US |
| Child | 18374236 | US |
